Circulating cytokines and angiogenic factors based signature associated with the relative dose intensity during treatment in patients with advanced hepatocellular carcinoma receiving lenvatinib

BACKGROUND: Although lenvatinib was recently approved for treatment of advanced unresectable hepatocellular carcinoma (HCC) based on the phase III REFLECT trial, no biomarkers for management of lenvatinib treatment have been established. The aim of this study is to identify predictive biomarkers for...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Ther Adv Med Oncol
Egile Nagusiak: Ono, Atsushi, Aikata, Hiroshi, Yamauchi, Masami, Kodama, Kenichiro, Ohishi, Waka, Kishi, Takeshi, Ohya, Kazuki, Teraoka, Yuji, Osawa, Mitsutaka, Fujino, Hatsue, Nakahara, Takashi, Murakami, Eisuke, Miki, Daiki, Kawaoka, Tomokazu, Abe-Chayama, Hiromi, Zhang, Peiyi, Liu, Songyao, Makokha, Grace Naswa, Tsuge, Masataka, Imamura, Michio, Hayes, C. Nelson, Chayama, Kazuaki
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: SAGE Publications 2020
Gaiak:
Early Diagnosis and Therapeutic Advances for Liver Cancer: From Bench to Bedside
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC7249573/
https://ncbi.nlm.nih.gov/pubmed/32547646
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1758835920922051
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak